Research & Literature
Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.
Top Authors
Top Institutions
Finding nearby institutions...
University of Freiburg
Freiburg im Breisgau, Germany
National Institutes of Health
Bethesda, United States
Hôpital Necker-Enfants Malades
Paris, France
University of Cambridge
Cambridge, United Kingdom
Charles University
Prague, Czechia
Great North Children's Hospital
Newcastle upon Tyne, United Kingdom
University of Rome Tor Vergata
Rome, Italy
Instituto de Biomedicina de Sevilla
Seville, Spain
Inserm
Paris, France
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
References
References (54)
- 1
Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
Olbrich P, Lorenz M, Cura Daball P, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2016; (27(6)):640-4 doi:10.1111/pai.12585.
PMID: 27116393 - 2
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E, Neven B, Bruneau J, et al.
The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.
PMID: 27221134 - 3
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI, Chandra A, Bacon CM, et al.
The Journal of allergy and clinical immunology 2017; (139(2)):597-606.e4 doi:10.1016/j.jaci.2016.06.021.
PMID: 27555459 - 4
Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.
Wentink M, Dalm V, Lankester AC, et al.
Clinical immunology (Orlando, Fla.) 2017; (176()):77-86 doi:10.1016/j.clim.2017.01.004.
PMID: 28104464 - 5
Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1.
Dornan GL, Siempelkamp BD, Jenkins ML, et al.
Proceedings of the National Academy of Sciences of the United States of America 2017; (114(8)):1982-1987 doi:10.1073/pnas.1617244114.
PMID: 28167755 - 6
Variant PIK3R1 Hypermorphic Mutation and Clinical Phenotypes in a Family with Short Statures, Mild Immunodeficiency and Lymphoma.
Hauck F, Magg T, Krolo A, et al.
Klinische Padiatrie 2017; (229(3)):113-117 doi:10.1055/s-0043-104218.
PMID: 28561224 - 7
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Condliffe AM, Chandra A
Frontiers in immunology 2018; (9()):338 doi:10.3389/fimmu.2018.00338.
PMID: 29556229 - 8
Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME, Abolhassani H, Aghamohammadi A, et al.
Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.
PMID: 29599784 - 9
Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T, Okada S, Tsumura M, et al.
Frontiers in immunology 2018; (9()):568 doi:10.3389/fimmu.2018.00568.
PMID: 29675019 - 10
CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome.
Cura Daball P, Ventura Ferreira MS, Ammann S, et al.
Immunology and cell biology 2018; (96(10)):1060-1071 doi:10.1111/imcb.12169.
PMID: 29790605 - 11
Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion.
Pham MN, Cunningham-Rundles C
Frontiers in pediatrics 2018; (6()):402 doi:10.3389/fped.2018.00402.
PMID: 30619796 - 12
Secondary C1q Deficiency in Activated PI3Kδ Syndrome Type 2.
Hong Y, Nanthapisal S, Omoyinmi E, et al.
Frontiers in immunology 2019; (10()):2589 doi:10.3389/fimmu.2019.02589.
PMID: 31781101 - 13
Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys.
Ewertowska M, Grześk E, Urbańczyk A, et al.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2020; (16()):22 doi:10.1186/s13223-020-00420-6.
PMID: 32265996 - 14
[Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase δ syndrome 2].
Yang QY, Jia YJ, Wang YP, et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; (58(5)):413-417 doi:10.3760/cma.j.cn112140-20190925-00614.
PMID: 32392959 - 15
Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase δ Syndrome 1: the First Case Series in Korea.
Kang JM, Kim SK, Kim D, et al.
Yonsei medical journal 2020; (61(6)):542-546 doi:10.3349/ymj.2020.61.6.542.
PMID: 32469178 - 16
Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Del Pino-Molina L, Torres Canizales JM, Rodríguez-Pena R, López-Granados E
Cytometry. Part B, Clinical cytometry 2021; (100(4)):460-466 doi:10.1002/cyto.b.21956.
PMID: 32961022 - 17
International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome.
Dimitrova D, Nademi Z, Maccari ME, et al.
The Journal of allergy and clinical immunology 2022; (149(1)):410-421.e7 doi:10.1016/j.jaci.2021.04.036.
PMID: 34033842 - 18
Infections in activated PI3K delta syndrome (APDS).
Brodsky NN, Lucas CL
Current opinion in immunology 2021; (72()):146-157 doi:10.1016/j.coi.2021.04.010.
PMID: 34052541 - 19
Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
Moreno-Corona N, Chentout L, Poggi L, et al.
Frontiers in pediatrics 2021; (9()):688022 doi:10.3389/fped.2021.688022.
PMID: 34249818 - 20
Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient.
Conti F, Catelli A, Cifaldi C, et al.
Frontiers in pediatrics 2021; (9()):702546 doi:10.3389/fped.2021.702546.
PMID: 34307262 - 21
Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.
Rivalta B, Amodio D, Milito C, et al.
Frontiers in pediatrics 2021; (9()):703853 doi:10.3389/fped.2021.703853.
PMID: 34540765 - 22
Psychological State of Parents of Children with Primary Immunodeficiencies During the COVID-19 Pandemic.
Akdağ B, Önder A, Gizli Çoban Ö, et al.
Pediatric allergy, immunology, and pulmonology 2022; (35(1)):12-18 doi:10.1089/ped.2021.0081.
PMID: 35180363 - 23
Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in PIK3R1 with reduced penetrance.
Szczawińska-Popłonyk A, Bernat-Sitarz K, Schwartzmann E, et al.
Allergologia et immunopathologia 2022; (50(4)):1-9 doi:10.15586/aei.v50i4.510.
PMID: 35789397 - 24
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
Rao VK, Webster S, Šedivá A, et al.
Blood 2023; (141(9)):971-983 doi:10.1182/blood.2022018546.
PMID: 36399712 - 25
Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
Nguyen T, Lau A, Bier J, et al.
The Journal of experimental medicine 2023; (220(6)) doi:10.1084/jem.20221020.
PMID: 36943234 - 26
Leniolisib: First Approval.
Duggan S, Al-Salama ZT
Drugs 2023; (83(10)):943-948 doi:10.1007/s40265-023-01895-4.
PMID: 37256490 - 27
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maccari ME, Wolkewitz M, Schwab C, et al.
The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.
PMID: 37390899 - 28
Activated PI3Kδ syndrome - reviewing challenges in diagnosis and treatment.
Vanselow S, Wahn V, Schuetz C
Frontiers in immunology 2023; (14()):1208567 doi:10.3389/fimmu.2023.1208567.
PMID: 37600808 - 29
Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant.
Tomlinson PR, Knox R, Perisic O, et al.
bioRxiv : the preprint server for biology 2024; doi:10.1101/2023.11.02.565250.
PMID: 38077044 - 30
Systematic review of mortality and survival rates for APDS.
Hanson J, Bonnen PE
Clinical and experimental medicine 2024; (24(1)):17 doi:10.1007/s10238-023-01259-y.
PMID: 38280023 - 31
Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.
Zhao P, Huang J, Fu H, et al.
Pediatric rheumatology online journal 2024; (22(1)):24 doi:10.1186/s12969-024-00955-7.
PMID: 38287413 - 32
The Dark Side of Activated Phosphoinositide 3-Kinase-δ Syndrome 2: A Story Rewritten through FDG-PET.
Catelli A, Nanni C, Mulè R, et al.
Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082203.
PMID: 38673479 - 33
[Activated phosphoinositide 3-kinase delta syndrome: report of seven cases].
Liu QH, Peng L, Huang H, et al.
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2024; (26(5)):499-505 doi:10.7499/j.issn.1008-8830.2312065.
PMID: 38802911 - 34
Health-related quality of life in patients with inborn errors of immunity: A systematic review and meta-analysis.
Xiao N, Huang X, Yang D, et al.
Preventive medicine 2024; (186()):108079 doi:10.1016/j.ypmed.2024.108079.
PMID: 39053518 - 35
Time to diagnosis for a rare disease: managing medical uncertainty. A qualitative study.
Phillips C, Parkinson A, Namsrai T, et al.
Orphanet journal of rare diseases 2024; (19(1)):297 doi:10.1186/s13023-024-03319-2.
PMID: 39143641 - 36
Case report on activated PI3K-delta syndrome.
Crisanto-López IE, Pérez-Arzola AA, Hernández-Castañeda Y, et al.
Boletin medico del Hospital Infantil de Mexico 2024; (81(4)):245-249 doi:10.24875/BMHIM.23000124.
PMID: 39236673 - 37
Immunodeficiency: Burden of Illness.
Hsueh JC, Van Hersh AT, Zhao W
Allergy and asthma proceedings 2024; (45(5)):294-298 doi:10.2500/aap.2024.45.240060.
PMID: 39294910 - 38
A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects.
Bildik HN, Esenboga S, Halaclı SO, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2024; (35(9)):e14245 doi:10.1111/pai.14245.
PMID: 39312287 - 39
Technical challenges of intracellular flow cytometry-based assays as a functional complement to diagnosis of signaling defects of inborn errors of immunity: PI3K pathway as a case of study.
Del Pino Molina L, Reche Yebra K, Soto Serrano Y, et al.
Frontiers in immunology 2024; (15()):1476218 doi:10.3389/fimmu.2024.1476218.
PMID: 39620215 - 40
Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review.
Büsch K, Memmott HL, McLaughlin HM, et al.
Advances in therapy 2025; (42(2)):752-771 doi:10.1007/s12325-024-03066-7.
PMID: 39636570 - 41
Case Report: Early-onset or recalcitrant cytopenias as presenting manifestations of activated PI3Kδ syndrome.
Remiker AS, Lopes JPM, Jesudas R, et al.
Frontiers in pediatrics 2024; (12()):1494945 doi:10.3389/fped.2024.1494945.
PMID: 39664282 - 42
Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.
IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ
Immunotherapy advances 2024; (4(1)):ltae009 doi:10.1093/immadv/ltae009.
PMID: 39679264 - 43
Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome in the Target Therapy Era.
Barzaghi F, Moratti M, Panza G, et al.
Journal of clinical immunology 2024; (45(1)):58.
PMID: 39714594 - 44
Listeria Meningitis as an Indication of Undiagnosed Primary Immune Deficiency, Activated Phosphoinositide 3-Kinase Delta Syndrome: A Case Report.
Canizci Erdemli P, Öcal Demir S, Bozkurt S, et al.
The Pediatric infectious disease journal 2025; (44(7)):672-675 doi:10.1097/INF.0000000000004737.
PMID: 39889727 - 45
Spanish Consensus on the Diagnosis and Management of Patients With Activated PI3K Delta Syndrome (APDS).
Neth O, Alsina L, Rivière JG, et al.
Journal of investigational allergology & clinical immunology 2025; (35(2)):87-102 doi:10.18176/jiaci.1059.
PMID: 40028901 - 46
Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS).
Mahendran M, Upton JEM, Ramasubramanian R, et al.
Orphanet journal of rare diseases 2025; (20(1)):212 doi:10.1186/s13023-025-03734-z.
PMID: 40319290 - 47
"It's a Godsend": Parental experiences of genomic testing for paediatric inborn errors of immunity.
Clark A, DeBortoli E, Blancoe M, et al.
European journal of human genetics : EJHG 2025; (33(10)):1342-1349 doi:10.1038/s41431-025-01917-7.
PMID: 40730688 - 48
Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application.
Upton JEM, Williams KW, Cant A, et al.
PloS one 2025; (20(10)):e0333341 doi:10.1371/journal.pone.0333341.
PMID: 41091701 - 49
Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.
Wolf HM, Candotti F, Spelsberg R, et al.
Frontiers in immunology 2026; (17()):1763482 doi:10.3389/fimmu.2026.1763482.
PMID: 41859081 - 50
Case Report: Recurrent pulmonary infections with neck masses: a diagnostic challenge and literature review.
Zhao L, Zhao J, Lu Y
Frontiers in medicine 2026; (13()):1807946 doi:10.3389/fmed.2026.1807946.
PMID: 42040580 - 51
Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder Complicated by Septic Shock in Activated PI3Kδ Syndrome: A Pediatric Case Report and Literature Review.
Zhao X, Ming X, Shang Z, et al.
Case reports in hematology 2026; (2026()):3644513 doi:10.1155/crh/3644513.
PMID: 42591980 - 52
Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety.
Rao VK, Šedivá A, Dalm VASH, et al.
Journal of human immunity 2027; (3(1)) doi:10.70962/jhi.20260040.
PMID: 42873197 - 53
Sirolimus and Immunoglobulin Replacement Therapy in Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS): A Systematic Literature Review.
Hartog NL, Pisarczyk K, Samad M, et al.
Advances in therapy 2026; doi:10.1007/s12325-026-03833-8.
PMID: 42932134 - 54
When cure is not enough: Parental anxiety, depression, and caregiver burden after HSCT for inborn errors of immunity.
Aydemir S, Durcan G, Nurhan E, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2026; (37(11)).
PMID: 42969273